A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Patients With Chronic Hepatitis B Infection
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 18 Aug 2017
At a glance
- Drugs Tenofovir disoproxil fumarate (Primary)
- Indications Hepatitis B
- Focus Registrational; Therapeutic Use
- Sponsors Gilead Sciences
- 10 Jun 2017 Biomarkers information updated
- 23 Dec 2016 Planned End Date changed from 1 Jun 2019 to 1 Mar 2025.
- 23 Dec 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Aug 2017.